Description: An Open-Label, Phase 1B Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Pegylated Liposomal Doxorubicin or Paclitaxel to Subjects with Platinum-Resistant Gynecological Cancers
Mechanism of Action: SL172154 Blocks antiphagocytic signal on cancer cells by attaching to SIRP alpha (receptor for CD47) and simultaneously engages costimulatory CD40L
Target Patient Population: High grade ovarian, primary peritoneal or fallopian tube cancers.
Study Design: Drug is given IV Day 1 and 8 of a 28 day cycle. Pegylated Liposomal Doxorubicin is given Standard of Care schedule